Takara Bio Inc
TSE:4974
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Takara Bio Inc
Total Current Assets
Takara Bio Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Takara Bio Inc
TSE:4974
|
Total Current Assets
¥42.8B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
3
|
3-D Matrix Ltd
TSE:7777
|
Total Current Assets
¥7.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
4%
|
|
|
SanBio Co Ltd
TSE:4592
|
Total Current Assets
¥2.3B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-12%
|
|
|
GNI Group Ltd
TSE:2160
|
Total Current Assets
¥40.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
26%
|
CAGR 10-Years
26%
|
|
|
PeptiDream Inc
TSE:4587
|
Total Current Assets
¥38.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Total Current Assets
¥4.5B
|
CAGR 3-Years
20%
|
CAGR 5-Years
12%
|
CAGR 10-Years
2%
|
|
Takara Bio Inc
Glance View
Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,539 full-time employees. The company went IPO on 2004-12-07. The firm operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
See Also
What is Takara Bio Inc's Total Current Assets?
Total Current Assets
42.8B
JPY
Based on the financial report for Dec 31, 2025, Takara Bio Inc's Total Current Assets amounts to 42.8B JPY.
What is Takara Bio Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
0%
Over the last year, the Total Current Assets growth was -20%. The average annual Total Current Assets growth rates for Takara Bio Inc have been -18% over the past three years .
